| 2.54 0.29 (12.89%) | 03-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.18 |
1-year : | 3.72 |
| Resists | First : | 2.73 |
Second : | 3.18 |
| Pivot price | 2.43 |
|||
| Supports | First : | 2.22 |
Second : | 1.91 |
| MAs | MA(5) : | 2.28 |
MA(20) : | 2.42 |
| MA(100) : | 3.67  |
MA(250) : | 4.02 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 22.9 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 15.6 | Low : | 1.91 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BGLC ] has closed below upper band by 35.5%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.68 - 2.69 | 2.69 - 2.7 |
| Low: | 2.22 - 2.23 | 2.23 - 2.24 |
| Close: | 2.52 - 2.54 | 2.54 - 2.55 |
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Tue, 17 Mar 2026
BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization - Stock Titan
Sun, 15 Mar 2026
BioNexus Gene Lab appoints commercial officer at Fidelion By Investing.com - Investing.com Nigeria
Wed, 11 Mar 2026
BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics - Quiver Quantitative
Wed, 11 Mar 2026
Cancer relapse blood tests: Fidelion hires 15-year oncology diagnostics veteran - Stock Titan
Mon, 09 Mar 2026
12 Industrials Stocks Moving In Monday's Intraday Session - Benzinga
Mon, 23 Feb 2026
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 36.3 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.78 |
| Profit Margin | -24.3 % |
| Operating Margin | -30.3 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -28.4 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 0.59 |
| Sales Per Share | 4.01 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.99 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0.63 |
| Price to Cash Flow | -2.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|